Nucleation

Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies

Retrieved on: 
火曜日, 5月 7, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Pillar, Harvard University, University, Cancer, Cache, International Society, American College, Cell, Laboratory, AUC, Harvard Business School, University Health Network, Biological engineering, Genetic, Software, Biophysical environment, Area studies, Biochemistry, RNA, Doctor of Philosophy, University Medical Center, Pathology, San Francisco Bay Area, Intelligence, ACMG, Stanford University, George Church, Bioethics, Chemistry, Faculty, MIT, MBA, SBIR, Yale School of Management, Temperature, Ageing, National Science Foundation, Dicarboxylic acid, Biology, Medical genetics, Nucleation, Computer data storage

Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.

Key Points: 
  • Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.
  • The funds will help power R&D and support commercial development efforts and key partnerships to bring their solutions to market.
  • “Over the past three decades, sequencing technologies have evolved drastically.
  • It feels like every month, a new sequencing method is developed,” says Michael Becich, Cache CEO.

Cromatic Closes $5.3 Million in Oversubscribed Seed Round to Modernize Life Science R&D Outsourcing

Retrieved on: 
木曜日, 11月 9, 2023
Science, Other Science, Biotechnology, Research, Health, Data Management, Health Technology, Technology, Food safety, Therapy, Life, ChromeOS, Nucleation, Russian Venture Company, Engineering, Growth, Lux Capital, Apple, VC, Cancer, SOSV, Communication, D, Fine chemical

Cromatic , a full-stack digital platform for outsourced life sciences research, today announced it has closed $5.3 million in funding.

Key Points: 
  • Cromatic , a full-stack digital platform for outsourced life sciences research, today announced it has closed $5.3 million in funding.
  • LifeX Ventures and AgFunder led the round with participation from Work Life Ventures, Not Boring Capital, FJ Labs, What If Ventures, Lux Capital, and angel investors.
  • The demand for biotech and pharmaceutical R&D outsourcing is growing rapidly and is expected to be worth $275 billion by 2030.
  • Cromatic is harnessing this newfound capacity in a coherent platform for a new generation of nimble and capital-efficient biotech companies.

Nuclearn.ai Announces $2.5M Series Seed; Round Led by Arizona Focused Venture Fund, AZ-VC

Retrieved on: 
水曜日, 8月 9, 2023
Partnership, Nucleation, LLM, Utility, Privacy, Machine learning, UWC, Growth, AI, Nuclear, Conference, Automation, Renewable energy, Online shopping

PHOENIX, Aug. 9, 2023 /PRNewswire/ -- Nuclearn.ai, a leading provider of AI process automation solutions for the nuclear industry, announced today at the Utility Working Conference and Vendor Technology Expo (UWC 2023) a Seed investment of $2.5M, led by AZ-VC with participation from Nucleation Capital. The round empowers Nuclearn.ai to grow its market leadership in nuclear facilities, scaling access to its AI and machine learning tools that improve how common, time-intensive tasks are managed across a broader array of energy facilities.

Key Points: 
  • The funds will be primarily used for hiring relationship-based sales teams focused on the North American nuclear power market and the general utility market.
  • Nuclearn.ai also plans to continue the development of AtomAssist, its Nuclear Language Model (LLM), and other utility-focused product use cases.
  • "With support from AZ-VC and Nucleation Capital, we are ready to expand our reach within the nuclear market," added Jerrold Vincent, co-founder of Nuclearn.ai.
  • "We're thrilled to invest in this industrious and talented team and support their vision of growth within the sector."

MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech Grant

Retrieved on: 
火曜日, 6月 6, 2023
Immortalised cell line, Osteoarthritis, Brain, Sigma-Aldrich, Körber Process Solutions, Biotechnology, Nucleation, Cancer, Merck Group, Ultrafiltration, RNA, Merck, Pharmaceutical industry, Vaccine

BURLINGTON, Mass., June 6, 2023 /PRNewswire/ -- MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced today that Proteologix US Inc. ("Proteologix") has been selected as the North American winner of its 12th Advance Biotech Grant program.

Key Points: 
  • BURLINGTON, Mass., June 6, 2023 /PRNewswire/ -- MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced today that Proteologix US Inc. ("Proteologix") has been selected as the North American winner of its 12th Advance Biotech Grant program.
  • "Our Advance Biotech Grant program provides emerging biotech companies with the expertise and resources they need to overcome the challenges of technical decision-making and regulatory hurdles on the path to commercialization."
  • Additionally, Proteologix will receive consultation services and training by technical experts from the Emprove® team and M Lab™ Collaboration Center.
  • In addition to MilliporeSigma's broad product portfolio and consultation services, Proteologix will also leverage the company's integrated Millipore® CTDMO Services.

Breakout Ventures Launches Partnership with Nucleate and Selects PhD Candidates and Postdocs for Fellowship Program

Retrieved on: 
火曜日, 5月 9, 2023
Research, Other Health, Entrepreneur, Pharmaceutical, Consumer, Other Education, Continuing, University, Education, Science, Biotechnology, Health, Other Science, Pillar, Breakout, San Francisco Bay Area, Engineering, Doctor of Philosophy, Harvard University, RNA, Fertilisation, Washington University in St. Louis, Associate, Wyss Institute for Biologically Inspired Engineering, Chemistry, Biochemistry, Entrepreneurship, Fellow, Structural biology, Wyss Institute, Fellows, Biology, Biophysics, Growth, Ecosystem, Gladstone Institutes, Bangladesh Technical Education Board, Management, Nursing, Nucleation, Venture

Breakout Fellows provide important connectivity to universities and research labs across the country, introduce new deals and support diligence with their expertise.

Key Points: 
  • Breakout Fellows provide important connectivity to universities and research labs across the country, introduce new deals and support diligence with their expertise.
  • The eight new fellows joining the program are:
    Garrett Ginell - PhD candidate in the Biochemistry, Biophysics, and Structural Biology program at Washington University in St. Louis.
  • Breakout Ventures has already invested in two Nucleate companies: EnPlusOne in Boston and Vitra Labs in the Bay Area.
  • “Breakout Ventures understands the tremendous potential of novel, early-stage research and values the determination of bold scientist-entrepreneurs,” said Lindy Fishburne, Managing Partner at Breakout Ventures.

Nucleate announces Eli Lilly and Company as a new Platinum Sponsor of the 2023 Activator program

Retrieved on: 
木曜日, 1月 5, 2023
Treasurer, Eli Lilly and Company, EVP, Eli Lilly, LLY, Activator, Regenerative medicine, Nucleation, Patient, NYSE, Entrepreneurship, Lilly, Pharmaceutical industry, Culture

BOSTON, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Nucleate, a nonprofit organization led by academic trainees and dedicated to empowering future biotech leaders, today announced that Eli Lilly and Company (NYSE: LLY) will become a Platinum Level Sponsor of the 2023 Activator Program. Nucleate's equity-free Activator program has supported more than 100 venture teams in their earliest stages of development, including Glyphic, NextRNA, and Manifold Bio. Lilly will be providing $300,000 in grants to promising technologies as part of the inaugural Eli Lilly and Company Genetic Medicine Grand Challenge.

Key Points: 
  • Nonprofit organization dedicated to empowering future biotech leaders, announced that Eli Lilly and Company (NYSE: LLY) will be a Platinum Sponsor of the 2023 Activator Program and inaugurate the $300K Genetic Medicine Grand Challenge.
  • BOSTON, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Nucleate , a nonprofit organization led by academic trainees and dedicated to empowering future biotech leaders, today announced that Eli Lilly and Company (NYSE: LLY) will become a Platinum Level Sponsor of the 2023 Activator Program.
  • Nucleate's equity-free Activator program has supported more than 100 venture teams in their earliest stages of development, including Glyphic, NextRNA, and Manifold Bio.
  • Lilly will be providing $300,000 in grants to promising technologies as part of the inaugural Eli Lilly and Company Genetic Medicine Grand Challenge.

GNS Appoints John Maraganore as Chair of the Board

Retrieved on: 
木曜日, 11月 3, 2022
Board, Chicago (franchise), RNA interference, Takeda Oncology, Patient, Chairperson, HIV disease progression rates, Investment, Neurology, Norwest Venture Partners, Agios Pharmaceuticals, University, Neurodegeneration, Molecular biology, GNS, Social media, Upjohn, Senior advisor, AI, M&A, Growth, Biogen, BIO, Biotechnology Innovation Organization, CEO, Advisory board, Research, Leadership, Digital twin, ZymoGenetics, RNA, Atlas Venture, Takeda Pharmaceutical Company, Industry, Nucleation, Therapy, Director, Partner, Business, The Advisory Board Company, Degenerative disease, Biochemistry, Pharmaceutical industry, Alnylam Pharmaceuticals, Inclisiran

Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.

Key Points: 
  • Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.
  • From his roles at Biogen to Millennium Pharmaceuticals to Alnylam, John is the rare individual who has brought innovation to market.
  • "I would like also to thank our outgoing Board Chair, Timothy Thompson, who will remain on the board, for his dedication and valuable service to GNS."
  • Dr. Maraganore is Chair Emeritus and a member of the Board of the Biotechnology Innovation Organization (BIO), where he was Chair from 2017-2019.

Skin turning brown like apples -- Korean research team suggests solutions

Retrieved on: 
水曜日, 1月 23, 2019
Human physiology, Human skin color, Skin care, Tyrosinase, Nucleation, Cosmetics

SEOUL, South Korea, Jan. 23, 2019 /PRNewswire/ -- DEMAR3,the cosmetics research team from Natural Substances Lab in South Korea, found that the cause of skin pigmentation is due to a substance called tyrosinase, the same substance responsiblefor making apples turn brown.

Key Points: 
  • SEOUL, South Korea, Jan. 23, 2019 /PRNewswire/ -- DEMAR3,the cosmetics research team from Natural Substances Lab in South Korea, found that the cause of skin pigmentation is due to a substance called tyrosinase, the same substance responsiblefor making apples turn brown.
  • The team presented their findings at a product launch conference in France on the 10th of January.
  • The research team, DEMAR3suggested a product called Etsere 62 Burning that utilizes nucleation effects as a solution to resolve the pigmentation of skin by oxidation.
  • The research team stated that "The nucleation effect was applied to Etsere 62 Burning in order to utilize the reaction to catalyze and amplify its effects."

Oscillating nanophase magnetite controls ice nucleation

Retrieved on: 
火曜日, 5月 8, 2018
Chemistry, Nature, Phase transitions, Magnetite, Spinel group, Nucleation, Crystallization, Ice, Magnetism

Kobayashi's team has now identified that material as the tiny magnetite crystals naturally present in most plant and animal tissues.

Key Points: 
  • Kobayashi's team has now identified that material as the tiny magnetite crystals naturally present in most plant and animal tissues.
  • Ice crystal nucleation is a fundamental feature of Earth's climate and environment, as well as that on other planets.
  • The magnetic effect on ice crystallization will influence any environment in which nanophase magnetite is a component.
  • Atsuko Kobayashi1*, Masamoto Horikawa2, Joseph L. Kirschvink1,3 and Harry N. Golash4, Magnetic Control of Heterogeneous Ice Nucleation with Nanophase Magnetite: Biophysical and Agricultural Implications, Proceedings of the National Academy of Sciences of the United States of America, DOI: http://www.pnas.org/cgi/doi/10.1073/pnas.1800294115
    2.